Is Receptor-Interacting Protein Kinase 3 a Viable Therapeutic Target for Mycobacterium tuberculosis Infection?

about

Is Receptor-Interacting Protein Kinase 3 a Viable Therapeutic Target for Mycobacterium tuberculosis Infection?

Item

http://www.wikidata.org/entity/Q54976471

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Is Receptor-Interacting Protei ...... terium tuberculosis Infection?

@en

Is Receptor-Interacting Protei ...... terium tuberculosis Infection?

@nl

type

Item

label

Is Receptor-Interacting Protei ...... terium tuberculosis Infection?

@en

Is Receptor-Interacting Protei ...... terium tuberculosis Infection?

@nl

prefLabel

Is Receptor-Interacting Protei ...... terium tuberculosis Infection?

@en

Is Receptor-Interacting Protei ...... terium tuberculosis Infection?

@nl

P1476

Is Receptor-Interacting Protei ...... terium tuberculosis Infection?

@en

P2093

Samar Ojaimi

http://www.w3.org/2001/XMLSchema#string

P2860

Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase

Allele-specific induction of IL-1β expression by C/EBPβ and PU.1 contributes to increased tuberculosis susceptibility

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

Identification of nitric oxide synthase as a protective locus against tuberculosis

RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Receptor-interacting protein (RIP) kinase family.

Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis

RIP kinases: key decision makers in cell death and innate immunity.

Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics.

P304

1178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.01178

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael D Stutz

Marc Pellegrini

Gregor Ebert

P577

2018-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29892302

http://www.w3.org/2001/XMLSchema#string

P921

Mycobacterium tuberculosis

P932

5985376

http://www.w3.org/2001/XMLSchema#string